Defibrination with ancrod in glomerulonephritis: effects on clinical and histologic findings and on blood coagulation.
Ancrod, which produces in vivo defibrination, has been shown to improve renal function and decrease fibrin deposition and crescents in experimental glomerulonephritis. Ancrod was given for 14 days to 5 patients with glomerulonephritis, moderate to severe renal functional impairment, crescents, and/or fibrin deposition in glomeruli. 4 patients had systemic lupus erythematosus. Ancrod treatment resulted in fibrinogen levels less than 50 mg/dl without bleeding, decrease of previously elevated factor VIII and von Willebrand factor levels, and normalization of in vitro platelet hyperaggregation. Renal function improved in all 5 patients. Serial renal biopsies showed a relatively rapid decrease of glomerular thrombi and necrosis and little increase in glomerular sclerosis. Ancrod administration appears safe, and may have a role in treatment of certain types of glomerulonephritis.
D000293:Adolescent; D000328:Adult; D000721:Ancrod / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects*; D005169:Factor VIII / Q000378:metabolism; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005921:Glomerulonephritis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D014841:von Willebrand Factor / Q000378:metabolism
D014841:von Willebrand Factor; D005169:Factor VIII; D005337:Fibrin; D005340:Fibrinogen; D000721:Ancrod